Product Name :
NVP-ACC-789
Description:
ACC-789, also known as NVP-ACC789 and ZK-202650, is a potent, selective and orally active inhibitor of the VEGF receptor tyrosine kinases with potential anticancer activity.
CAS:
300842-64-2
Molecular Weight:
405.29
Formula:
C21H17BrN4
Chemical Name:
N-(3-Bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine
Smiles :
CC1=CC=C(C=C1Br)NC1=NN=C(CC2C=CN=CC=2)C2=CC=CC=C21
InChiKey:
GXWKSXUPEFVUOO-UHFFFAOYSA-N
InChi :
InChI=1S/C21H17BrN4/c1-14-6-7-16(13-19(14)22)24-21-18-5-3-2-4-17(18)20(25-26-21)12-15-8-10-23-11-9-15/h2-11,13H,12H2,1H3,(H,24,26)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
ACC-789, also known as NVP-ACC789 and ZK-202650, is a potent, selective and orally active inhibitor of the VEGF receptor tyrosine kinases with potential anticancer activity.|Product information|CAS Number: 300842-64-2|Molecular Weight: 405.29|Formula: C21H17BrN4|Synonym:|ACC-789|ZK-202650|NVP-ACC789|NVP-ACC 789|NVP-ACC-789|ACC 789|ACC789|ZK 202650|ZK202650|Chemical Name: N-(3-Bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine|Smiles: CC1=CC=C(C=C1Br)NC1=NN=C(CC2C=CN=CC=2)C2=CC=CC=C21|InChiKey: GXWKSXUPEFVUOO-UHFFFAOYSA-N|InChi: InChI=1S/C21H17BrN4/c1-14-6-7-16(13-19(14)22)24-21-18-5-3-2-4-17(18)20(25-26-21)12-15-8-10-23-11-9-15/h2-11,13H,12H2,1H3,(H,24,26)|Technical Data|Appearance: Solid Power.|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO, not in water|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined.{{Vindesine} site|{Vindesine} Microtubule/Tubulin|{Vindesine} Technical Information|{Vindesine} Formula|{Vindesine} custom synthesis|{Vindesine} Cancer} |HS Tariff Code: 382200|How to use|In Vitro:|The enzymatic kinase assays demonstrate that NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.{{Netropsin} MedChemExpress|{Netropsin} Antibiotic|{Netropsin} Immunology/Inflammation|{Netropsin} Technical Information|{Netropsin} Formula|{Netropsin} supplier} 38, 0.02 (0.23), 0.18, 1.4 μM, respectively. In VEGF-treated cultures, addition of the VEGFR-2 inhibitor NVP-ACC789 reduces BME cell number to baseline levels from 1 μM. Likewise, bFGF-induced BME cell proliferation is reduced markedly by NVP-ACC789 from 1 to 10 μM, without however reaching basal levels.PMID:25429455 NVP-ACC789 is found to be a potent inhibitor of VEGF-induced HUVE cell proliferation with an IC50 of 1.6 nM. NVP-ACC789 also completely inhibits VEGF-induced BME and BAE cell invasion and VEGF-C-induced BAE cell invasion. The inhibition is dose-dependent in both cell types with a maximal effect from 1 μM.|In Vivo:|NVP-ACC789 which is given in daily oral doses for 6 days blocks VEGF-induced angiogenesis in a dose-dependent manner. NVP-ACC789 also inhibits the response to bFGF to some extent, but the dose-response curve is not linear for NVP-ACC789.|References:|Tille JC, et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basicfibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther. 2001 Dec;299(3):1073-85.Products are for research use only. Not for human use.|